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Background: Fibrostenosis and stricture are well-recognized endpoints in Crohn’s disease (CD). We hypothesized that stricturing CD is characterized
by eosinophilia and epithelial IL-33. We proposed that eosinophil exposure to IL-33 would perpetuate inflammatory chronicity and subsequent
fibrostenosis.
Methods: We performed a retrospective study of 74 children with inflammatory and stricturing ileal CD comparing clinicopathological features to
immunohistochemical measures of eosinophilia and IL-33. To scrutinize eosinophil patterns, we developed a novel eosinophil peroxidase score
encompassing number, distribution, and degranulation. Human eosinophils and intestinal fibroblasts were cultured with IL-33 and IL-13, and inflammatory
and remodeling parameters were assessed. Antieosinophil therapy was also administered to the Crohn’s-like ileitis model (SAMP1/SkuSlc).
Results: Our novel eosinophil peroxidase score was more sensitive than H&E staining, revealing significant differences in eosinophil patterns, comparing
inflammatory and stricturing pediatric CD. A significant relationship between ileal eosinophilia and complicated clinical/histopathological phenotype
including fibrosis was determined. IL-33 induced significant eosinophil peroxidase secretion and IL-13 production. Exposure to eosinophils in the presence
of IL-33, “primed” fibroblasts to increase proinflammatory cytokines (TNF-a, IL-1b, and IL-6), eosinophil-associated chemokines (CCL24 and CCL26), and
IL-13Ra2 production. Production of fibrogenic molecules (collagen 1A2, fibronectin, and periostin) increased after exposure of “primed” fibroblasts to
IL-13. Epithelial-IL-33 was increased in pediatric Crohn’s ileitis and strongly associated with clinical and histopathological activity, ileal eosinophilia, and
complicated fibrostenotic disease. SAMP1/SkuSlc eosinophil-targeted treatment resulted in significant improvements in inflammation and remodeling.
Conclusions: Our study of specimens from pediatric patients with ileal CD linked eosinophil patterns and IL-33 to fibrosis and suggested that these
may contribute to the perpetuation of inflammation and subsequent stricture in pediatric CD.
(Inflamm Bowel Dis 2015;21:2429–2440)
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T he underlying pathogenesis of Crohn’s disease (CD) relates tothe complex interactions between genetic, immunologic, and
environmental factors. In some cases, chronic inflammation leads
to stricture formation and surgical resection of diseased tissue.
Although not all patients develop intestinal strictures, ileal loca-
tion and duration of disease pose specific risks.1 In fact, the
cumulative incidence of stricturing disease has been reported as
27% at 5 years and 38% at 10 years.2 Although certain similarities
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exist between pediatric and adult onset disease, pediatric disease
is distinct with more extensive and rapidly progressing pathol-
ogy.3 Thus, studies focusing specifically on pediatric patients are
of great value to gain a better understanding of cause and
improved treatments or preventions. Without an exact understand-
ing of the underlying pathogenesis of stricturing disease, the iden-
tification of biomarkers, therapeutic targets, and thus Food and
Drug Administration–approved treatments remains undiscovered.
Previous studies link CD-related strictures with a number of
different cell types including fibroblasts and eosinophils. With
respect to eosinophils, a large body of evidence supports their role
in tissue remodeling and fibrosis. For instance, eosinophils and
eosinophil-derived products induced the activation of fibroblasts
in vitro, resulting in fibroblast proliferation, collagen gel contrac-
tion, and production of fibrogenic molecules, remodeling pro-
teases, cytokines, and chemokines.4–6 However, to date, no
study has examined the relationship between eosinophil patterns
in stricturing pediatric CD compared with those with inflamma-
tory pediatric CD. In addition, IL-33 has not been examined com-
paring stricturing to inflammatory pediatric CD populations.
Using a mouse model of CD, others and we previously reported
the significant association of eosinophils with mouse ileitis and
identified their potential as a novel therapeutic target.7,8 Because
these results provided support for a clinically relevant role for
eosinophils in fibrotic CD and because of the identified role of
eosinophils in other fibrotic diseases, we wondered whether eosin-
ophil patterns were different in complicated pediatric CD such as
stricturing disease compared with inflammatory CD. To address
this, we hypothesized that eosinophils were associated with stric-
tured CD in children and that the profibrogenic cytokines, IL-33
and IL-13, stimulated a remodeling response from human eosino-
phils and intestinal fibroblasts.
METHODS
Assessment of Antieosinophil Treatment in
Mouse Ileitis
Original SAMP1 strain of the mouse model of Crohn’s-like
ileitis, SAMP1/SkuSlc female mice 4 to 10 weeks of age, were
purchased from Japan SLC (Hamamatsu, Japan).9 Mice were
maintained under specific pathogen-free conditions with ad libi-
tum access to food and water. Anti-CCR3 rat anti-mouse MAb
6S2-19-4 and monoclonal antibody specific for interleukin-5
(TRFK-5; Cayman Chemical, Ann Arbor, MI) both selectively
deplete murine eosinophils.7,10,11 Experimental animals were in-
jected intraperitoneally with 200 mg of TRFK-5 antibody, 200 mg
of anti-CCR3 and 200 mg of TRFK-5 antibodies once weekly
from 20 to 30 weeks of age and killed 24 hours after final admin-
istration. Inflamed control mice were treated intraperitoneally with
a nonspecific isotype control antibody with equal dose and dura-
tion. The last 10 cm of the ileum was removed, processed, and
scored by a pathologist blinded to the experimental conditions
(P.J.) as previously described.7,12
Briefly, 3 histological parameters were assessed with equal
weight for each parameter: (1) active inflammation (granulocytes),
(2) chronic inflammation (lymphoplasmacytic infiltrates), and (3)
villus distortion (architectural disruption, separation of villi, crypts,
and muscularis). Infiltrating eosinophils were identified by immu-
nostaining with rat anti-mouse major basic protein monoclonal
antibody (Clone MT-14.7) and quantified as previously described.7
Ileal sections were stained with periodic acid–Schiff, and goblet
cells were quantified as previously described as a measure of re-
modeling.7 The University of Colorado School of Medicine Insti-
tutional Animal Care and Use Committee approved these studies.
Subject Selection
A retrospective chart review was performed of patients who
were evaluated in the Digestive Health Institute, Section of
Pediatric Gastroenterology, Hepatology, and Nutrition at the
Children’s Hospital Colorado from 2002 to 2011 who had
received a diagnosis of CD and had undergone surgical resection
(stricturing) or biopsy (inflammatory) of the terminal ileum. Sub-
jects were excluded from this analysis if they had incomplete
treatment records. Based on review of the clinical record, subjects
were subdivided into either stricturing or nonstricturing ileal dis-
ease. Subjects were defined as follows: stricturing CD subjects
exhibited symptoms and radiological features consistent with par-
tial obstruction that lead to surgical resection; inflammatory CD
subjects had symptoms and clinical evidence of inflammation
(laboratories and/or radiographs) without evidence of obstruction;
and control subjects had symptoms of gastrointestinal dysfunc-
tion, no clinical evidence of inflammation (laboratories and/or
radiographs) and normal ileal mucosa. Patients were consid-
ered under CD treatment if they were prescribed either
5-aminosalicylates, corticosteroids, immunomodulators, biologic
therapies, or antibiotics alone or in combination. Clinical features
recorded included location(s) of activity, previous treatments,
ESR, CRP, and HgB units and calculation of Pediatric Crohn’s
Disease Activity Index (PCDAI) (Table 1).13
Human Subject Specimen
Histological Assessments
To allow for equal comparison between biopsies and full
thickness resected tissues, all histological assessments were
performed on mucosal tissue alone and not on deeper resected
tissues. Hematoxylin and Eosin (H&E)–stained ileal tissue sec-
tions were assessed by board certified pathologist (K.E.C.) for (1)
pathological activity (mild active, mild, moderate, or severe
chronic active); (2) eosinophil numbers (mean of 5 random high
powered fields [HPF] and peak number counted in single most
densely inflamed HPF at ·40 magnification field size 0.26 mm2,
data presented as mean 6 range); and (3) lamina propria fibrosis
(mild, loose collagen matrix fibrils; moderate, condensed collagen
matrix fibrils; or severe, substantially condensed collagen matrix
fibrils) (see Fig. A, Supplemental Digital Content 1, http://links.
lww.com/IBD/B2). Measurement of lamina propria fibrosis was
also performed on Masson’s Trichrome stained tissue sections.
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Eosinophil peroxidase (EPX) immunostaining was com-
pleted to determine the pattern of eosinophils within tissue
specimens. Briefly, each section underwent staining with a mono-
clonal antibody for EPX (hybridoma MM25-82.2.1) as previously
described.11,14 Slides were assessed for eosinophil patchiness/local-
ization, degranulation, and intact eosinophil numbers to determine
an ileal EPX index adapted from that previously described (see
Table, Supplemental Digital Content 2, http://links.lww.com/IBD/
B3 and Fig. B, Supplemental Digital Content 1, http://links.lww.
com/IBD/B2).14 Priority factors were assigned based on those indi-
ces that gave the greatest and the least differences when comparing
inflammatory to stricturing specimens allowing stratification of
these 2 disease types. On this basis, priorities were assigned to
patchiness/localization (priority score: 4), average numbers of
eosinophil infiltrating the tissues (priority score: 3), peak eosinophil
number infiltrating the tissue (priority score: 2), and degranulation
(priority score: 1). Tissue sections were assessed independently and
in a blinded manner by a pathologist (K.E.C.) and 2 other research
investigators (J.C.M. and L.H.).
Immunostaining was completed for interleukin-33 (poly-
clonal goat anti-IL-33; R&D Systems, Minneapolis, MN). Slides
were assessed for IL-33 staining as follows: none: score 0, present
in epithelial cells: score 1, or increased numbers of/presence in
epithelial cells: score 2. IL-33–stained tissue sections were as-
sessed independently by 3 research investigators (L.H., R.H.,
and S.D.F.) blinded to specimen demographics. The Institutional
Review Board at the University of Colorado (COMIRB) approved
this study.
Human Eosinophil Isolation
Human eosinophils were isolated from healthy volunteers.
Briefly, white blood cells were isolated from whole blood and
anticoagulated with 5% citrate buffer. Plasma was removed after
centrifugation. Red blood cells were pelleted from leukocytes using
6% dextran/0.9% saline sedimentation (Fluka; Sigma, St. Louis,
MO). Granulocytes were isolated from discontinuous Percol gra-
dients (42% and 51%) (Sigma), and monocytes discarded. Residual
erythrocytes were lysed with ice-cold water, and the remaining cells
were washed. Eosinophils were purified by negative selection using
anti-CD16 and anti-CD14 MACS microbeads and AutoMACS
separation (Miltenyi, Auburn, CA). Eosinophils were .95% pure
as assessed by fast green (4%). The Institutional Review Board at the
University of Colorado (COMIRB) approved this study.
Assessment of Eosinophil Activation by IL-33
Viable single-cell suspensions were subjected to culture in
the presence or absence of 100 ng/mL IL-33 (R&D Systems) for 3
hours. Cells were subjected to flow cytometric analysis with
FITC-labeled anti-ST2 or isotype control antibodies (MBL Inter-
national, Woburn, MA). EPX release into cell supernatants was
quantified as a marker of eosinophil activation and granule protein
release by peroxidase assay, modified from that previously
described.15 Eosinophils were also pelleted by centrifugation
and harvested for electron microscopic analysis in glutaraldehyde
fixative as previously described16 or harvested for total cell RNA
isolation with RNeasy Mini Kits (Qiagen, Valencia, CA). Taqman
gene expression assays (Applied Biosystems, Foster City, CA)
were performed on whole-cell RNA, processed as previously
described.11 Data were normalized to 18S and calculated as Rel-
ative Expression (22DDCt).
Eosinophil and 18Co Fibroblast Coculture
Intestinal myofibroblasts (18Co-ATCC) were cultured as
previously described4 in the presence of freshly isolated
TABLE 1. Clinical Characteristics of Study Subjects
Control Inflammatory Stricturing
Number (n) 39 17 18
Sex (% male) 44 59 67
Age range (median), yr 2–17 (14) 6–17 (14) 8–18 (14)
Disease duration, mo NA 8.0 6 2.9 11.3 6 2.5
ESR, mm/h 10.0 6 1.7 32.3 6 6.7 35.7 6 6.8
CRP, mg/dL 0.5 6 0.04 6.2 6 3.7 9.3 6 2.1
Hgb, g/dL 13.6 6 0.4 12.0 6 0.4 11.4 6 0.5
Previous treatments Corticosteroid: 0 Corticosteroid: 6 Corticosteroid: 15
5-ASA: 0 5-ASA: 4 5-ASA: 4
Immunomodulator: 0 Immunomodulator: 6 Immunomodulator: 17
Biologic: 0 Biologic: 1 Biologic: 4
Antibiotic: 0 Antibiotic: 5 Antibiotic: 2
PCDAI NA 35.2 6 1.9 37.6 6 2.3
All values mean 6 SEM.
No statistical difference between inflammatory and stricturing disease was obtained.
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eosinophils at a ratio of 1:1. After 24 or 48 hours of coculture,
eosinophils were completely removed and 18Co cells harvested
for total cell RNA isolation with RNeasy Mini Kits (Qiagen). For
IL-13 stimulation experiments, 18Co cells were cocultured with
eosinophils for 48 hours, eosinophils were removed, and 18Co
cells were returned to culture in the presence of IL-13 (100 ng/mL;
R&D Systems) for an additional 72 hours at which point 18Cos
were harvested for total cell RNA isolation with RNeasy Mini Kits
(Qiagen).
Statistical Analyses
Statistical analyses of data outcomes were performed by
Mann–Whitney U test, 1-way analysis of variance (Kruskal
Wallis) test with Dunn’s correction for multiple comparisons,
1-way analysis of variance (Newman–Keuls) test, Spearman rank
correlation test, and Student’s t test where appropriate. Data are
expressed as mean 6 SEM. A P value of #0.05 was considered
as statistical significance although in some cases, higher levels of
significance are noted and described in the figure legends where
applicable (*P # 0.05, **P # 0.01, ***P # 0.001).
RESULTS
Eosinophil Targeted Therapies Diminished
Chronic Inflammation and Remodeling in
a Mouse Model of Crohn’s-like Ileitis
To examine the causative effects of eosinophils on tissue
remodeling, the SAMP1/SkuSlc mouse model of Crohn’s-like dis-
ease was treated with eosinophil-targeting antibodies (TRFK-5 or
anti-CCR3 and TRFK-5 in combination). A significant improve-
ment in overall inflammation and tissue architecture was deter-
mined by examining H&E-stained ileal tissue sections (14.8 6
1.8 versus 4.6 6 0.5; P , 0.001 versus 4.7 6 1.7 total inflam-
matory score; P , 0.01) (see Fig. A, Supplemental Digital Con-
tent 3, http://links.lww.com/IBD/B4). As expected, treatment with
both antibody regimens led to a significant reduction in ileal tissue
eosinophils as quantified on major basic protein–stained sections
(200 6 22 versus 82 6 14; P , 0.01 versus 46 6 3 eosinophils/
HPF; P , 0.001) (see Fig. B, Supplemental Digital Content 3,
http://links.lww.com/IBD/B4). As a measure of remodeling, gob-
let cell hyperplasia assessed by periodic acid–Schiff staining was
significantly decreased in these anti-eosinophil–treated mice com-
pared with age-matched immunoglobulin G–treated controls
(30 6 3 versus 13 6 1; P , 0.001 versus 11 6 1 percent goblet
cells per villus; P , 0.001) (see Fig. C, Supplemental Digital
Content 3, http://links.lww.com/IBD/B4).
Eosinophil Mucosal Distribution Pattern
Differentiates Stricturing from Nonstricturing
Pediatric Ileal CD
Next, we determined whether any histopathological fea-
tures present in the mucosal surface of clinical specimens from
pediatric subjects permitted the distinction of inflammatory from
stricturing CD. Clinical characteristics of stricturing CD subjects
(n ¼ 18), inflammatory Crohn’s subjects (n ¼ 17), and control
subjects (n ¼ 39) are presented in Table 1. Subjects were included
in this study who were both treatment naive and those undergoing
medical treatments for CD (5-aminosalicylates, corticosteroids,
immunomodulators, biologic therapies, or antibiotics alone or in
combination). No statistical differences were identified between
stricturing and inflammatory CD subjects when comparing mean
disease duration and laboratory markers of inflammation (ESR,
CRP, and HgB) (Table 1). We next determined whether the
number of eosinophils, as traditionally counted on H&E-stained
tissues were able to provide distinguishing histological features
of these 2 phenotypes. Whereas peak eosinophil counts, as mea-
sured by H&E, were increased in inflammatory CD compared
with control subjects (P , 0.001), they were not significantly
increased comparing control subjects to stricturing CD speci-
mens (Fig. 1A, C–E).
On H&E staining, the tinctural features of eosinophils and
their granules, in the context of an inflamed mucosa, can make
enumeration challenging. Based on this, we questioned whether
a more comprehensive assessment of mucosal eosinophil patterns
might be beneficial. To address this, we took advantage of our
previously developed EPX immunohistochemical staining proto-
col using this on these ileal tissue specimens. Results from this
more sensitive and specific staining could now identify a signifi-
cant increase in peak eosinophil number comparing stricturing CD
specimens to control subjects (P , 0.001) (Fig. 1B–E).
To further address this difference in sensitivity between
H&E and EPX analysis, a 4-point EPX immunohistochemistry-
based indexed scoring system was adapted from our previous
work14 to better characterize eosinophil patterns in the ileal
mucosa of stricturing and inflammatory CD specimens (Table 1).
EPX scoring analysis revealed a significant increase in eosinophil
burden when comparing controls (12.97 6 0.54; EPX-score) with
inflammatory (16.64 6 0.97; P , 0.01) to stricturing CD speci-
mens (19.616 0.9; P, 0.001) (Fig. 2A). In contrast to using just
peak eosinophil numbers (Fig. 2D), a significant increase in eosin-
ophil pattern as assessed by total EPX score (patchiness/distribu-
tion, degranulation and numbers combined) was captured in the
stricturing CD specimens as compared with inflammatory CD (P
, 0.05) (Fig. 2A). Further dissection of differences between
inflammatory and structuring CD mucosal eosinophilia revealed
differences in patchiness or distribution/localization of eosino-
phils (7.12 6 0.44 versus 5.52 6 0.46; P , 0.05, stricturing
versus inflammatory) (Fig. 2B) and average number of eosino-
phils counted across 5 fields of view (6.92 6 0.34 versus 6.06 6
0.32; stricturing versus inflammatory) (Fig. 2E). Neither peak
number of eosinophils nor degranulation could distinguish
between stricturing and inflammatory CD specimens (Fig. 2C,
D). Analysis of tissue from treatment-naive subjects showed sim-
ilar patterns; eosinophil EPX-score was increased in stricturing
and inflammatory CD subjects compared with control subjects
(see Fig. C, Supplemental Digital Content 4, http://links.lww.
com/IBD/B5).
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Ileal Eosinophilia Correlates with
Clinicopathological Features of Pediatric CD
To address the potential association of eosinophils with
disease activity, we next correlated the peak number of eosino-
phils as identified by EPX staining with the PCDAI and
histological features of chronicity and fibrosis. To exclude any
potential treatment-effect bias, only treatment-naive specimens
were examined. This comparison revealed a highly significant
relationship between the peak numbers of eosinophils/HPF and
PCDAI (r ¼ 0.68, P , 0.0001; Fig. 2F). In addition, a highly
significant association was identified between eosinophilia and
histological chronicity (r ¼ 0.76, P , 0.0001; Fig. 2G) and fibro-
sis (r ¼ 0.68, P , 0.0001; Fig. 2H). The relationship between
eosinophilia and fibrosis was also confirmed when examining
fibrosis assessed by Masson’s Trichrome stain (r ¼ 0.33, P ,
0.01). Together, these results indicate that mucosal eosinophilia is
associated with chronicity and complications in pediatric Crohn’s
ileitis, and that detailed analysis of mucosal eosinophil patterns
provides significant benefit in clinically and histologically char-
acterizing inflammatory versus stricturing pediatric CD.
Eosinophils Are Activated by IL-33 and Prime
Intestinal Fibroblasts in the Perpetuation of
Eosinophil Recruitment and Exacerbated
Fibrosis Through IL-13
We next took a reductionist approach to determine the
impact of eosinophils in intestinal fibrosis. Based on previous
work suggesting a role for IL-33 in eosinophil and fibrosis-
related diseases, we first determined the ability of IL-33 to
induce eosinophil degranulation and the production of fibrogenic
cytokines associated with inflammatory bowel disease (IBD)
such as IL-13.17 We first confirmed that human eosinophils ex-
pressed the cognate IL-33 receptor ST2 by flow cytometry; sim-
ilar to previously published studies, we show that 18.3%6 6.9%
of resting human eosinophils express ST2 (n ¼ 3 donors). Next,
we found that the exposure of human eosinophils to IL-33
resulted in eosinophil activation observed by electron micro-
graph, including membrane ruffling and reversal of granule
staining consistent with degranulation (Fig. 3A). IL-33 stimu-
lated eosinophils also resulted in significant release of EPX
compared with controls, as captured by immunofluorescence
assay (Fig. 3B). Finally, we examined the ability of IL-33 to
induce human eosinophil-derived fibrogenic IL-13, as had pre-
viously been demonstrated for mouse eosinophils. These results
demonstrated a significant increase in IL-13 mRNA synthesis
(19-fold; P , 0.01) (Fig. 3C).
To further determine the downstream impact of IL-33–
stimulated eosinophils, we examined whether these activated leu-
kocytes could induce a proinflammatory response from intestinal
fibroblasts (Fig. 4). Our results showed that coculture of IL-33–
stimulated eosinophils with intestinal fibroblasts led to increased
production of a number of inflammatory (TNF-a, IL-1b, and
IL-6) and eosinophil chemotactic (CCL24 and CCL26) molecules
(Fig. 4A, B). For instance, compared with control fibroblasts,
TNF-a was significantly increased by the presence of IL-33–
stimulated eosinophils (10-fold; P , 0.05 [24 h]) (7-fold; P ,
0.01 [48 h]) (Fig. 4A). IL-1b was increased 3.4-fold (P , 0.05
[24 h]) (Fig. 4A), whereas IL-6 was increased 2-fold (P , 0.05
[24 h]) and 13.5-fold (P ¼ 0.18 [48 h]) (Fig. 4A).
FIGURE 1. Eosinophil patterns are distinguishable between mucosa
of inflammatory and stricturing CD. Peak numbers of eosinophils
were enumerated in (A) H&E and (B) EPX-stained ileal tissues from
patients with CD. Subjects were divided into those with strictures
(STR) and those without strictures that had inflammatory CD (INFL).
Representative photomicrographs comparing H&E to EPX-stained
tissues from control (CL), inflammatory, and stricturing Crohn’s-ilea
(A-C). Scale bars represent 50 mM. Data are expressed as mean 6
SEM. Statistical significance was assessed by 1-way analysis of vari-
ance with Newman–Keuls multiple comparisons test. *P # 0.05, ***P
# 0.001.
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In addition, the increased production of the eosinophil-
associated chemokines CCL24 (Eotaxin-2) and CCL26 (Eotaxin-3)
also demonstrated the potential for further eosinophil
recruitment by fibroblasts. Compared with control fibroblasts,
CCL24 was significantly increased by the presence of IL-33–
stimulated eosinophils (7-fold; P , 0.01 [24 h]) (4.2-fold; P ,
0.01 [48 h]) (Fig. 4B). CCL26 was increased 1.7-fold (P , 0.05
[24 h]) (Fig. 4B), and changes in CCL11 (Eotaxin-1) production
were not found.
The expression of the cytokine receptor IL-13Ra2 was also
significantly increased (Fig. 4C-iii). IL-13Ra2 has been described
as a mediator of IL-13–induced intestinal fibrosis or as an IL-13
antagonist in other organs.18,19 To investigate the role of increased
fibroblast IL-13Ra2 expression after IL-33–stimulated eosinophil
coculture, we followed this coculture by removing the eosinophils
and secreted mediators and subsequently stimulated these
“primed” intestinal fibroblasts with IL-13 in fresh media. Fibro-
blasts first cultured in the presence of IL-33–stimulated eosino-
phils and subsequently stimulated with IL-13–induced significant
production of COL1A2 when compared with fibroblasts first cul-
tured in the presence of eosinophils alone with subsequent IL-13
stimulation (4.5-fold versus 3.3-fold; P , 0.05) (Fig. 4D). A
similar induction of fibronectin (1.7-fold versus 1.5-fold; P ,
0.05), and periostin (11.7-fold versus 6.5-fold; P , 0.05) was
also established (Fig. 4D). Here, we determined a clear 2-step
method by which IL-33–stimulated eosinophils mediate the
“priming” of intestinal fibroblasts for subsequent IL-13–induced
profibrotic activity.
FIGURE 2. Distinguishing stricturing Crohn’s ileitis using EPX immunohistochemistry-based scoring system. Eosinophil infiltration correlates with
disease activity, chronicity, and fibrosis. EPX immunohistochemistry provides a quantitatively sensitive strategy to distinguish inflammatory from
stricturing CD specimens. Examination of the scores for individual EPX parameters associated with all control (CL), inflammatory (INFL), or
stricturing (STR) patients with CD found in Table 1 demonstrated differences between (A) their overall scores, in addition to individual parameters
comprising the EPX algorithm: (B) patchiness, (C) degranulation, (D) peak eosinophils/HPF, and (E) average eosinophils across 5 random fields of
view (F.O.V.). Statistical assessments (analysis of variance with Newman–Keuls) of the EPX staining scores (mean 6 SEM) demonstrated the utility
of this algorithm to distinguish between stricturing and inflammatory CD mucosal specimens. *P # 0.05, **P # 0.01, ***P # 0.001. Peak numbers
of ileal eosinophils/HPF (EPX) were analyzed for relationships to subjects’ (F) PCDAI, (G) histological activity and (H) fibrosis score measured in H&E-
stained tissues for subjects defined in Table 1 that were not considered under treatment relevant to their CD. The Pearson’s correlation coefficient
(r) and its associated statistical significance are shown.
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IL-33 Is Increased in Pediatric Ileal CD and
Associated with Eosinophilia and Histological
Evidence of Disease Chronicity
Because IL-33 can stimulate the influx of eosinophils into
inflamed tissues and elicit their activation, we next examined
intestinal epithelial IL-33 in pediatric tissues affected by CD using
immunohistochemistry (Fig. 5). IL-33 was most strongly detected
in endothelial cell nuclei and in infiltrating lamina propria cells,
epithelial cells, Paneth cell granules and could sometimes be de-
tected as cell-free cytokine within extracellular spaces. Epithelial
IL-33 was detected more frequently in epithelial cells of the crypts
than villi and was located in both the cytoplasm and nucleus of
these cells, consistent with previous reports examining Crohn’s
and ulcerative colitis specimens.20–22 Epithelial IL-33 was signif-
icantly increased in untreated inflammatory (1.6 6 0.08; P ,
0.001) and stricturing (1.3 6 0.06; P , 0.001) CD subjects’
specimens compared with controls (0.45 6 0.05) (Fig. 5A, B).
Interestingly, CD-related treatments had no effect on epithelial
IL-33 levels in either group. Correlation analysis determined
a significant relationship between the increasing presence of
epithelial IL-33 and PCDAI (r ¼ 0.75, P , 0.001), histologic
activity (r ¼ 0.71, P , 0.001), and numbers of eosinophils (r ¼
0.6, P , 0.001) (Fig. 5C–E). A significant correlation was also
detected between epithelial IL-33 and fibrosis (r ¼ 0.5969, P ,
0.001) (Fig. 5F). A modest but statistically significant relation-
ship existed between cell-free/extracellular IL-33 and eosinophil
degranulation (r ¼ 0.2760, P , 0.05) in addition to fibrosis (r ¼
0.4529, P ¼ 0.001).
DISCUSSION
Fibrostenotic ileal CD represents a poorly understood
pediatric patient phenotype that frequently requires surgical
resection. Identification of predisposing factors, novel biomarkers,
and therapeutic targets associated with this group of patients could
provide earlier diagnosis and medical intervention. Because of an
increasing body of work that supports a role for eosinophils in
fibrotic diseases outside of the gastrointestinal tract, we wondered
whether accumulation and activation of this cell was associated
with pediatric ileal stricturing CD. To address this, we used
immunohistochemical staining for EPX to fully capture a number
of key features related to eosinophil infiltration and translated our
findings to assess the role of IL-33, a key fibrogenic molecule, in
activating eosinophils to promote a stenotic phenotype. Histolog-
ical assessments with EPX revealed that the degree and localiza-
tion pattern of eosinophilic inflammation distinguished stricturing
pediatric CD compared with inflammatory pediatric CD. In
addition, our data elucidate the lack of sensitivity, specifically
in fibrostenotic pediatric CD, of H&E staining for the study of
eosinophils’ role(s) in intestinal inflammation. Activation of eo-
sinophils by IL-33 led not only to degranulation but also to pro-
duction of IL-13 and fibroblast production of a number of
downstream molecules associated with fibrosis. Together, these
findings provide support for a possible pathogenetic role of eosi-
nophils in the remodeling events that lead to pathological fibros-
tenosis in pediatric CD.
Clinical studies examining eosinophils’ role in IBD, espe-
cially those focusing on complicated pediatric CD, are limited due
to a number of factors including small numbers of patients, inad-
equate methodologies to detect eosinophils, variability of eosino-
phil number along the gastrointestinal tract, and lack of
information regarding treatments taken by study subjects before
specimen procurement. In fact, few studies have defined a “nor-
mal” number of eosinophils along the gastrointestinal tract of
children, thus making comparisons between control and diseased
tissues difficult. Regarding our overall hypothesis, we carefully
defined this unique and large group of ileal stenotic pediatric
patients and compared them with relevant pediatric noninflamed
controls. To address a central issue of capturing the full content of
eosinophilic inflammation, we used an eosinophil granule-specific
immunohistochemical stain to develop a scoring index rather than
just using the single metric of eosinophil number. Careful and
FIGURE 3. Circulating eosinophils are activated by IL-33. Circulating
eosinophils were isolated and subjected to IL-33 stimulation (100 ng/
mL) for 3 hours and then assessed for evidence of activation. A,
Representative electron micrographs provide evidence of eosinophil
activation (right) compared with untreated controls (left), including
reversal of granule staining consistent with degranulation (arrows),
and membrane ruffling (arrowheads). B, Biochemical measures of
peroxidase activity in cell-free supernatants from control and IL-33–
stimulated eosinophils (3 h, 100 ng/mL) were performed. C, Eosinophil
IL-13 mRNA expression analysis was performed by real-time PCR on
extracted RNA from control and IL-33–stimulated eosinophils (3 h, 100
ng/mL). Data are expressed as mean 6 SEM of 4 individual donors.
Statistical significance was assessed using the nonparametric
Mann–Whitney U test compared with untreated controls. *P # 0.05,
**P # 0.01.
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FIGURE 4. IL-33–activated eosinophils induce proinflammatory intestinal fibroblast activation and perpetuation of eosinophil recruitment in vitro.
Confluent 18Co intestinal fibroblasts cells were cocultured with IL-33 (100 ng/mL) and eosinophils. As controls 18Co cells treated with IL-33 alone
(100 ng/mL), 18Co cells cocultured with eosinophils in the absence of IL-33 or 18Co cells alone were used. A, Proinflammatory cytokine, (B)
eosinophilic chemokine, and (C) cytokine receptor mRNA analysis of 18Co fibroblasts was performed by real-time PCR on extracted RNA after 24
and 48 hours of coculture. In a second series of experiments, cells were treated in the 4 groups described above. After 48 hours of coculture, 18Co
cells were washed and IL-13 (100 ng/mL) was placed into each of the wells. D, Fibrosis-associated molecule mRNA analysis of IL-13–stimulated
18Co fibroblasts was performed by real-time PCR on extracted RNA after an additional 72 hours of culture. Data are expressed as mean6 SEM of 2
to 6 individual donors. Statistical significance was assessed using 1-way analysis of variance with Newman–Keuls multiple comparisons test. *P #
0.05, **P # 0.01, ***P # 0.001.
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thorough patient selection and tissue analysis created the unique
set of findings presented here.
A number of previous studies have documented the
profound accumulation of eosinophils in mucosal tissues from
patients with pathologically and phenotypically undefined IBD,
but their role within this microenvironment remains uncertain. An
urgent need exists to begin targeting specific mechanisms
including eosinophils’ role in specific aspects of mucosal dysfunc-
tion. In this regard, eosinophils have been shown to participate
directly as an effector cell in barrier dysfunction, goblet cell
hyperplasia, and muscle contraction.7,23,24 In the intestine, eosino-
phils in vitro have been directly implicated in the activation of
intestinal fibroblasts, resulting in fibroblast proliferation, the pro-
duction of fibronectin, collagen, collagen gel contraction, IL-6
and IL-8 secretion.4–6 In addition, eosinophils may communicate
with other resident cells to initiate or perpetuate an inflammatory
response. In support of our results, recent in vitro studies exam-
ined the impact of IL-33 on not only fibrosis but also eosinophil
activation. For instance, IL-33–stimulated eosinophils adhere to
matrix and connective tissue proteins and secrete significant quan-
tities of IL-8 compared with control eosinophils.25–29 Exposure of
mouse bone marrow–derived eosinophils to IL-33 results in the
production of IL-13.30 Because human eosinophils are one of the
key sources of IL-13, we sought to determine whether IL-33 could
FIGURE 5. Epithelial IL-33 expression is associated with disease progression and eosinophilia in complicated CD. Representative photomicro-
graphs of IL-33 immuohistochemically stained ileal tissues from (A-i) control (CL) subjects or from patients with (A-ii) inflammatory (INFL) or (A-iii)
stricturing (STR) CD. Arrows indicate epithelial-IL-33. B, A score was generated to quantify the absence (0), presence (1), or increased presence (2)
of epithelial IL-33 staining. Epithelial IL-33 scores were analyzed for relationships to subjects’ (C) PCDAI, (D) histological activity, and (E) peak
eosinophils/HPF (EPX), and (F) fibrosis score measured in H&E-stained tissues. All analyses were performed on subjects defined in Table 1, which
were not considered under treatment relevant to their CD. Statistical significance was assessed for epithelial IL-33 scores by using 1-way analysis
of variance with Newman–Keuls multiple comparisons test. ***P # 0.001. For all other analysis, the Pearson’s correlation coefficient (r) and its
associated statistical significance are shown.
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directly stimulate IL-13 production and for the first time show this
in human eosinophils.30–38 In addition, coculture of “primed”
fibroblasts with IL-33–activated eosinophils led to increased
IL-13Ra2 expression and downstream to IL-13–induced profi-
brotic molecule expression. These findings bear relevance since
Fichtner-Feigl et al previously defined the crucial role of IL-13
signaling through IL-13Ra2 in intestinal fibrosis using chronic
mouse models.18,39–41
To date, eosinophil production of IL-13 has not been
studied in the context of eosinophil–fibroblast interactions and the
subsequent activation and perpetuation of fibrogenic processes in
the intestines. Here, we show for the first time in a reductionist
setting that eosinophil–fibroblast or IL-33–eosinophil–fibroblast
cocultures lead to the induction of IL-13Ra2. Subsequent expo-
sure of these intestinal fibroblasts to IL-13 leads to the production
of fibrogenic molecules collagen 1a2, fibronectin, and periostin.
Thus, eosinophils may contribute in a 2-step manner towards both
perpetuation of inflammation and the potentiation of profibrotic
activation of intestinal fibroblasts in vitro.
Fibrosis is considered a sequela to chronic inflammation,
thus cytokines are an important factor in this process. IL-33 is
produced by a wide range of cells in IBD including colonocytes20,22
and colitis-associated myofibroblasts.42,43 Previous studies have
defined that IL-33 is increased in active IBD samples compared
with uninvolved or control specimens.20–22,42–45 Not all studies refer
to the site of specimen collection; however, there is enough evi-
dence currently to state that IL-33 expression is increased in
colonic IBD and seems most prominent in ulcerative colitis. Stud-
ies of CD and IL-33 have been limited in specimen number and
mainly to colonic location. IL-33 has been implicated in the fibrotic
process in other organs.17,46–50 Thus, ours is the first significantly
powered study of IL-33 comparing inflammatory and stricturing
disease in pediatric Crohn’s ileitis specimens. We report here that
epithelial IL-33 is increased in ileal localized pediatric Crohn’s
IBD. This IL-33 is associated with increased PCDAI, histological
activity, eosinophilic infiltration, and more severe fibrosis score.
The clinical relevance of these findings is based on 2 highly
significant correlations. First, while our novel metrics of eosin-
ophilic inflammation was able to distinguish inflammatory from
structuring pediatric CD, peak eosinophil values were also highly
correlative with PCDAI and histological features of chronicity
and fibrosis. Second, epithelial IL-33 expression in ileal tissues
was also highly correlative with eosinophilia, PCDAI, and
histological evidence of chronicity.51,52
Our findings are consistent with a growing body of interest
and that of our previous study that suggested the association between
eosinophils and bowel wall thickening in pediatric patients with
eosinophilic colitis and with esophageal remodeling in eosinophilic
esophagitis.53,54 Here, using a new and more potent double-antibody
eosinophil-targeted treatment, we reinforce our previous findings
demonstrating the positive impact of single-antibody eosinophil-
targeted treatment on ileal inflammation and remodeling.7
The pathogenesis of CD-related strictures is not fully
understood, but ileal disease and duration of disease are
considered risk factors. The cells most implicated in this process
are those of mesenchymal origin including fibroblasts, smooth
muscle cells, and recruited or transdifferentiated mesenchymal-
like cells.55 Once activated by profibrogenic mediators such as
TGF-b and IL-13, these cells proliferate and produce fibrotic
molecules such as collagen, fibronectin, and periostin. The pro-
duction of an excessive amount of these cells and molecules leads
to tissue thickening and stiffness and eventually to stricture.
Growing evidence supports a new paradigm whereby fibroblasts
contribute to initiation and perpetuation of inflammatory pro-
cesses independent of their structural and fibrogenic roles during
chronic disease.56 Another study of colonic myofibroblasts has
shown that type-2 cytokines regulate the eosinophil–chemokine
eotaxin-3 expression.57 Here, we provide evidence for the first time
that eosinophils and, in addition, IL-33–stimulated eosinophils
induce intestinal fibroblast production of proinflammatory cytokines
TNF-a, IL-1b, and IL-6 and eosinophilic–chemokines eotaxin-2
(CCL24) and eotaxin-3 (CCL26). Thus, IL-33–eosinophil–fibroblast
interactions may act to perpetuate intestinal inflammation and eosin-
ophilia by both cytokine and chemokine production.
Our findings are limited by the lack of longitudinal data
from our specimens. Future studies should consider examining
eosinophilia over the course of disease in paired samples before
and after stricturing in addition to increased numbers of speci-
mens with and without treatment. Due to the rare nature of these
specimens, this should be a heavily powered long-term study.
Similar to coculture experiments reported here, studies examining
eosinophils’ role in esophageal and dermal fibroblast activation
determined the necessity for contact between eosinophils and
fibroblasts.29,31 Future studies should examine the role of soluble
mediators versus juxtacrine signaling between eosinophils and
fibroblasts in mediating inflammatory and fibrogenic processes.
Previous studies have associated epithelial IL-33 with inflamma-
tory ulcerative colitis in adults. Here, we report associations
between epithelial IL-33 and fibrostenotic pediatric Crohn’s ilei-
tis. Future studies need to consider dissection of IL-33 in fibrotic
clinical complications of chronic disease, including quantitative
comparisons between these 2 anatomical sites. Clinical implica-
tions of our study now highlight the need to examine eosinophilia
when histologically assessing specimens from patients with CD.
Our data demonstrate that altered mucosal eosinophil patterns
determined by our EPX scoring system can differentiate inflam-
matory versus stricturing ileal mucosal specimens, and that this is
independent of disease duration.
Here, we have added to previous studies in mouse models
indicating that eosinophils play a significant role in ileal remodeling
and fibrosis in specimens from pediatric patients with CD. These
studies established that fibrosis occurring in pediatric ileal CD is
associated with greater eosinophilic inflammation, epithelial IL-33
expression and mediated in part by IL-33, eosinophils, and IL-13
signaling in intestinal fibroblasts. Additional studies are planned to
address a longitudinal examination of eosinophils in the pro-
gression toward fibrosis in pediatric and adult CD. Our data add to
a growing body of literature dissecting the mechanisms of
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fibrostenosis in CD, implicating eosinophils and eosinophil-derived
mediators as viable targets in CD-related strictures.
ACKNOWLEDGMENTS
The authors wish to thank the members of all the
participating laboratories and the members of the Gastrointestinal
Eosinophilic Diseases Program Children’s Hospital Colorado for
insightful discussions and critical comments. They also wish to
acknowledge the invaluable assistance in animal husbandry and
care at University of Colorado School of Medicine (Kristann
Magee) and the administrative support provided by Joshua
Rosenfeld, Linda Mardel, and Shirley (“Charlie”) Kern. They
gratefully thank Eric Wartchow for technical assistance on elec-
tron microscopy. They thank the physicians (Robert Kramer,
Edward Hoffenberg, Edwin Liu, E. F. de Zoeten, David
Brumbaugh, Christine Waasdorp, Shikha Sundaram, Cara Mack,
Michael Narkewicz, Ronald Sokol, Jason Soden, and Deborah
Neigut), and nurses (Tammy Armstrong, Sharon Mooney, and
Jo Anne Newton), research assistants (Zachary Robinson and
Joseph Ruybal), pathology staff (Sara Garza), research coordina-
tors (Wendy Moore and Alyson Yeckes), and endoscopy techni-
cal staff (Bill Markovich) who contributed to this work by helping
to provide and collect samples. We are grateful to our patients and
families who were part of this study.
REFERENCES
1. Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with
progression to intestinal complications of Crohn’s disease in a population-
based cohort. Gastroenterology. 2010;139:1147–1155.
2. Gupta N, Bostrom AG, Kirschner BS, et al. Incidence of stricturing and
penetrating complications of Crohn’s disease diagnosed in pediatric pa-
tients. Inflamm Bowel Dis. 2010;16:638–644.
3. Henderson P, van Limbergen JE, Wilson DC, et al. Genetics of
childhood-onset inflammatory bowel disease. Inflamm Bowel Dis.
2011;17:346–361.
4. Furuta GT, Ackerman SJ, Varga J, et al. Eosinophil granule-derived major
basic protein induces IL-8 expression in human intestinal myofibroblasts.
Clin Exp Immunol. 2000;122:35–40.
5. Gomes I, Mathur SK, Espenshade BM, et al. Eosinophil-fibroblast inter-
actions induce fibroblast IL-6 secretion and extracellular matrix gene
expression: implications in fibrogenesis. J Allergy Clin Immunol. 2005;
116:796–804.
6. Xu X, Rivkind A, Pikarsky A, et al. Mast cells and eosinophils have
a potential profibrogenic role in Crohn disease. Scand J Gastroenterol.
2004;39:440–447.
7. Masterson JC, McNamee EN, Jedlicka P, et al. CCR3 Blockade Attenu-
ates Eosinophilic Ileitis and Associated Remodeling. Am J Pathol. 2011;
179:2302–2314.
8. Takedatsu H, Mitsuyama K, Matsumoto S, et al. Interleukin-5 participates
in the pathogenesis of ileitis in SAMP1/Yit mice. Eur J Immunol. 2004;
34:1561–1569.
9. Takeda T, Hosokawa M, Takeshita S, et al. A new murine model of
accelerated senescence. Mech Ageing Dev. 1981;17:183–194.
10. Justice JP, Borchers MT, Crosby JR, et al. Ablation of eosinophils leads to
a reduction of allergen-induced pulmonary pathology. Am J Physiol Lung
Cell Mol Physiol. 2003;284:L169–L178.
11. Masterson JC, McNamee EN, Fillon SA, et al. Eosinophil-mediated sig-
nalling attenuates inflammatory responses in experimental colitis. Gut.
2014;64:1236–1247.
12. McNamee EN, Wermers JD, Masterson JC, et al. Novel model of TH2-
polarized chronic ileitis: the SAMP1 mouse. Inflamm Bowel Dis. 2010;16:
743–752.
13. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of
a pediatric Crohn’s disease activity index. J Pediatr Gastroenterol Nutr.
1991;12:439–447.
14. Protheroe C, Woodruff SA, de Petris G, et al. A novel histologic scoring
system to evaluate mucosal biopsies from patients with eosinophilic
esophagitis. Clin Gastroenterol Hepatol. 2009;7:749–755.e711.
15. Colgan SP, Dzus AL, Parkos CA. Epithelial exposure to hypoxia
modulates neutrophil transepithelial migration. J Exp Med. 1996;184:
1003–1015.
16. Capocelli KE, Fernando SD, Menard-Katcher C, et al. Ultrastructural
features of eosinophilic oesophagitis: impact of treatment on desmosomes.
J Clin Pathol. 2015;68:51–56.
17. Rankin AL, Mumm JB, Murphy E, et al. IL-33 induces IL-13-dependent
cutaneous fibrosis. J Immunol. 2010;184:1526–1535.
18. Fichtner-Feigl S, Strober W, Kawakami K, et al. IL-13 signaling through
the IL-13alpha2 receptor is involved in induction of TGF-beta1 produc-
tion and fibrosis. Nat Med. 2006;12:99–106.
19. Mentink-Kane MM, Wynn TA. Opposing roles for IL-13 and IL-13 recep-
tor alpha 2 in health and disease. Immunol Rev. 2004;202:191–202.
20. Beltran CJ, Nunez LE, Diaz-Jimenez D, et al. Characterization of the
novel ST2/IL-33 system in patients with inflammatory bowel disease.
Inflamm Bowel Dis. 2010;16:1097–1107.
21. Pastorelli L, Garg RR, Hoang SB, et al. Epithelial-derived IL-33 and its
receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/
Th2 driven enteritis. Proc Natl Acad Sci U S A. 2010;107:8017–8022.
22. Seidelin JB, Bjerrum JT, Coskun M, et al. IL-33 is upregulated in colo-
nocytes of ulcerative colitis. Immunol Lett. 2010;128:80–85.
23. Furuta GT, Nieuwenhuis EE, Karhausen J, et al. Eosinophils alter colonic
epithelial barrier function: role for major basic protein. Am J Physiol
Gastrointest Liver Physiol. 2005;289:G890–G897.
24. Jacoby DB, Gleich GJ, Fryer AD. Human eosinophil major basic protein
is an endogenous allosteric antagonist at the inhibitory muscarinic M2
receptor. J Clin Invest. 1993;91:1314–1318.
25. Cherry WB, Yoon J, Bartemes KR, et al. A novel IL-1 family cytokine,
IL-33, potently activates human eosinophils. J Allergy Clin Immunol.
2008;121:1484–1490.
26. Chow JY, Wong CK, Cheung PF, et al. Intracellular signaling mecha-
nisms regulating the activation of human eosinophils by the novel Th2
cytokine IL-33: implications for allergic inflammation. Cell Mol Immunol.
2010;7:26–34.
27. Pecaric-Petkovic T, Didichenko SA, Kaempfer S, et al. Human basophils
and eosinophils are the direct target leukocytes of the novel IL-1 family
member IL-33. Blood. 2009;113:1526–1534.
28. Suzukawa M, Koketsu R, Iikura M, et al. Interleukin-33 enhances adhe-
sion, CD11b expression and survival in human eosinophils. Lab Invest.
2008;88:1245–1253.
29. Wong CK, Leung KM, Qiu HN, et al. Activation of eosinophils interact-
ing with dermal fibroblasts by pruritogenic cytokine IL-31 and alarmin IL-
33: implications in atopic dermatitis. PLoS One. 2012;7:e29815.
30. Bouffi C, Rochman M, Zust CB, et al. IL-33 markedly activates murine
eosinophils by an NF-kappaB-dependent mechanism differentially depen-
dent upon an IL-4-driven autoinflammatory loop. J Immunol. 2013;191:
4317–4325.
31. Rieder F, Nonevski I, Ma J, et al. T-helper 2 cytokines, transforming
growth factor beta1, and eosinophil products induce fibrogenesis and alter
muscle motility in patients with eosinophilic esophagitis. Gastroenterol-
ogy. 2014;146:1266–1277.e1261–1269.
32. Schmid-Grendelmeier P, Altznauer F, Fischer B, et al. Eosinophils
express functional IL-13 in eosinophilic inflammatory diseases.
J Immunol. 2002;169:1021–1027.
33. Aceves SS, Chen D, Newbury RO, et al. Mast cells infiltrate the esoph-
ageal smooth muscle in patients with eosinophilic esophagitis, express
TGF-b1, and increase esophageal smooth muscle contraction. J Allergy
Clin Immunol. 2010;126:1198–1204.e1194.
34. Aceves SS, Newbury RO, Dohil R, et al. Esophageal remodeling in
pediatric eosinophilic esophagitis. J Allergy Clin Immunol. 2007;119:
206–212.
35. Dyer KD, Percopo CM, Xie Z, et al. Mouse and human eosinophils
degranulate in response to platelet-activating factor (PAF) and lysoPAF
via a PAF-receptor-independent mechanism: evidence for a novel recep-
tor. J Immunol. 2010;184:6327–6334.
Inflamm Bowel Dis  Volume 21, Number 10, October 2015 Eosinophils, IL-33, and Fibrosis in Crohn’s Ileitis
www.ibdjournal.org | 2439
Copyright © 2015 Crohn’s & Colitis Foundation of America, Inc. Unauthorized reproduction of this article is prohibited.
D
ow
nloaded from
 https://academ
ic.oup.com
/ibdjournal/article-abstract/21/10/2429/4644929 by M
aynooth U
niversity user on 25 February 2020
36. Spencer LA, Szela CT, Perez SA, et al. Human eosinophils constitutively
express multiple Th1, Th2, and immunoregulatory cytokines that are
secreted rapidly and differentially. J Leukoc Biol. 2009;85:117–123.
37. Stolarski B, Kurowska-Stolarska M, Kewin P, et al. IL-33 exacerbates
eosinophil-mediated airway inflammation. J Immunol. 2010;185:3472–3480.
38. Woerly G, Lacy P, Younes AB, et al. Human eosinophils express and
release IL-13 following CD28-dependent activation. J Leukoc Biol. 2002;
72:769–779.
39. Fichtner-Feigl S, Fuss IJ, Young CA, et al. Induction of IL-13 triggers
TGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sul-
fonic acid colitis. J Immunol. 2007;178:5859–5870.
40. Fichtner-Feigl S, Strober W, Geissler EK, et al. Cytokines mediating the
induction of chronic colitis and colitis-associated fibrosis. Mucosal Immu-
nol. 2008;1(suppl 1):S24–S27.
41. Fichtner-Feigl S, Young CA, Kitani A, et al. IL-13 signaling via IL-13R
alpha2 induces major downstream fibrogenic factors mediating fibrosis in
chronic TNBS colitis. Gastroenterology. 2008;135:2003–2013, 2013.
e2001–2007.
42. Sponheim J, Pollheimer J, Olsen T, et al. Inflammatory bowel disease-
associated interleukin-33 is preferentially expressed in ulceration-
associated myofibroblasts. Am J Pathol. 2010;177:2804–2815.
43. Kobori A, Yagi Y, Imaeda H, et al. Interleukin-33 expression is specifi-
cally enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol.
2010;45:999–1007.
44. Sedhom MA, Pichery M, Murdoch JR, et al. Neutralisation of the
interleukin-33/ST2 pathway ameliorates experimental colitis through
enhancement of mucosal healing in mice. Gut. 2013;62:1714–1723.
45. Wakahara K, Baba N, Van VQ, et al. Human basophils interact with
memory T cells to augment Th17 responses. Blood. 2012;120:4761–4771.
46. Li D, Guabiraba R, Besnard AG, et al. IL-33 promotes ST2-dependent
lung fibrosis by the induction of alternatively activated macrophages and
innate lymphoid cells in mice. J Allergy Clin Immunol. 2014;134:1422–
1432.e1411.
47. Luzina IG, Kopach P, Lockatell V, et al. Interleukin-33 potentiates
bleomycin-induced lung injury. Am J Respir Cell Mol Biol. 2013;49:
999–1008.
48. Sanchez-Mas J, Lax A, Asensio-Lopez Mdel C, et al. Modulation of IL-
33/ST2 system in postinfarction heart failure: correlation with cardiac
remodelling markers. Eur J Clin Invest. 2014;44:643–651.
49. Marvie P, Lisbonne M, L’Helgoualc’h A, et al. Interleukin-33 overexpres-
sion is associated with liver fibrosis in mice and humans. J Cell Mol Med.
2010;14:1726–1739.
50. McHedlidze T, Waldner M, Zopf S, et al. Interleukin-33-dependent innate
lymphoid cells mediate hepatic fibrosis. Immunity. 2013;39:357–371.
51. Bailey JR, Bland PW, Tarlton JF, et al. IL-13 promotes collagen accu-
mulation in Crohn’s disease fibrosis by down-regulation of fibroblast
MMP synthesis: a role for innate lymphoid cells? PLoS One. 2012;7:
e52332.
52. Scharl M, Frei S, Pesch T, et al. Interleukin-13 and transforming growth
factor b synergise in the pathogenesis of human intestinal fistulae. Gut.
2013;62:63–72.
53. Brandon JL, Schroeder S, Furuta GT, et al. CT imaging features of eosin-
ophilic colitis in children. Pediatr Radiol. 2013;43:697–702.
54. Kagalwalla AF, Akhtar N, Woodruff SA, et al. Eosinophilic esophagitis:
epithelial mesenchymal transition contributes to esophageal remodeling
and reverses with treatment. J Allergy Clin Immunol. 2012;129:1387–
1396.e1387.
55. Rieder F, Fiocchi C. Intestinal fibrosis in inflammatory bowel disease:
progress in basic and clinical science. Curr Opin Gastroenterol. 2008;
24:462–468.
56. Li M, Riddle SR, Frid MG, et al. Emergence of fibroblasts with a proin-
flammatory epigenetically altered phenotype in severe hypoxic pulmonary
hypertension. J Immunol. 2011;187:2711–2722.
57. Takahashi K, Imaeda H, Fujimoto T, et al. Regulation of eotaxin-3/CC
chemokine ligand 26 expression by T helper type 2 cytokines in human
colonic myofibroblasts. Clin Exp Immunol. 2013;173:323–331.
Masterson et al Inflamm Bowel Dis  Volume 21, Number 10, October 2015
2440 | www.ibdjournal.org
Copyright © 2015 Crohn’s & Colitis Foundation of America, Inc. Unauthorized reproduction of this article is prohibited.
D
ow
nloaded from
 https://academ
ic.oup.com
/ibdjournal/article-abstract/21/10/2429/4644929 by M
aynooth U
niversity user on 25 February 2020
